Last reviewed · How we verify
NCT04463953
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Phase 2 trial testing Zanubrutinib,Ixazomib and Dexamethasone in Waldenström Macroglobulinemia in 25 participants. Completed in 6 December 2022.
6 December 2022
Quick facts
| Lead sponsor | Institute of Hematology & Blood Diseases Hospital, China |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 1 June 2020 |
| Primary completion | 6 December 2022 |
| Estimated completion | 6 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Zanubrutinib,Ixazomib and Dexamethasone — full drug profile →
Conditions studied
- Waldenström Macroglobulinemia — all drugs for Waldenström Macroglobulinemia →
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Who can join
18 and older, any sex, with Waldenström Macroglobulinemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the efficacy of BTK inhibitor Zanubrutinib combined with Ixazomib and Dexamethasone (ZID) for the newly diagnosed Waldenstrom Macroglobulinemia. This ZID regimen will be given up to 24 months and stopped for observation. We propose this combination will improve the deep remission (≥VGPR) compared to single Zanubrutinib or IRD regimen and can be a time-limited regimen which will reduce the life-time therapy and benefit the patients.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Managing Waldenström's macroglobulinemia with BTK inhibitors.
Buske C, Jurczak W, Salem JE, Dimopoulos MA. · · 2023 · cited 26× · PMID 36402930 · DOI 10.1038/s41375-022-01732-9 -
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Castillo JJ, Buske C, Trotman J, Sarosiek S, et al · · 2023 · cited 17× · PMID 36415104 · DOI 10.1002/ajh.26788 -
Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Muñoz J, Wang Y, Jain P, Wang M. · · 2022 · cited 13× · PMID 35651781 · DOI 10.1177/20406207221093980 -
Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions.
Wolska-Washer A, Robak T. · · 2023 · cited 11× · PMID 37035197 · DOI 10.3389/fonc.2023.1130595 -
Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia.
Muñoz J, Paludo J, Sarosiek S, Castillo JJ. · · 2022 · cited 7× · PMID 36291152 · DOI 10.3390/cells11203287 -
Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.
Deshpande A, Munoz J. · · 2022 · cited 6× · PMID 35770040 · DOI 10.2147/tcrm.s338655 -
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.
Tomowiak C, Poulain S, Nudel M, Feugier P, et al · · 2025 · cited 2× · PMID 39499299 · DOI 10.1007/s00277-024-06076-1 -
Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study.
Xiong W, Yan Y, Wang T, Sui W, et al · · 2025 · cited 1× · PMID 40053705 · DOI 10.1158/1078-0432.ccr-24-3490
Verify or expand the search:
- PubMed search for NCT04463953
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Waldenström Macroglobulinemia
Currently open trials in the same condition.
- NCT06986174 — A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemi · Phase 2 · recruiting
- NCT05294731 — Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Deg · Phase 1, PHASE2 · recruiting
- NCT01815749 — Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent · Phase 1 · active not recruiting
Other Institute of Hematology & Blood Diseases Hospital, China trials
Trials by the same sponsor.
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
- NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04463953 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
- Last refreshed: 11 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04463953.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing